Eli Lilly and Co.
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Eli Lilly scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Eli Lilly increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Eli Lilly forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Eli Lilly has also spoken out against state efforts to reform its own election processes. The company pledged $25 million to BLM and related causes and denounced religious freedom legislation. Eli Lilly has also funded Planned Parenthood and multiple LGBT organizations. For these reasons, Eli Lilly receives a High Risk rating.
Board Bias
Expand Summary
CEO of Eli Lilly and Co.
David A. Ricks
Summary:
Headquartered in Indianapolis, Indiana, Eli Lilly and Co. is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. David A. Ricks and David A. Ricks serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $314,600 to Republican causes and $109,987 to Democratic causes. Under their tenure, Eli Lilly and Co. currently holds a 'High Risk' risk rating.
Political Contributions of Leadership:
$314,600
$109,987
Republican
Democrat
Shareholder Proposals
Expand Summary
Date | ESG Category | Proponent | Summary of Resolution | Mgmt Rec | Total Vote % in Favor |
---|---|---|---|---|---|
5/1/23 | Governance | John Chevedden | Eliminate Supermajority Voting Requirements | Against | 40.70% |
5/1/23 | Governance | SEIU Master Trust | Report Disclosing Lobbying Activity | Against | 31.40% |
5/1/23 | Social | As You Sow | Report on the Effectiveness of the Company's Diversity, Equity, and Inclusion Efforts | Against | 27.10% |
5/1/23 | Social | As You Sow, on behalf of Leslie Oelsner Bene IRA of S Berman (S), Sarah B Sonnenfeld Rev Tr (S), Curtis Overway and Marcelina Cravat-Overway | Greater Disclosure of Material Corporate Diversity | Against | 27.10% |
5/1/23 | Governance | CommonSpirit Health | Report on Lobbying Values Congruency | Against | 22.50% |
5/1/23 | Social | Trinity Health | Report on Impact of Patent Process on Product Access | Against | 10.40% |
5/1/23 | Governance | Change Finance | Require Indirect Political Spending Reporting | Against | 4.10% |
5/1/23 | Social | National Center for Public Policy | Report on Risks of Supporting Abortion | Against | 1.90% |
5/2/22 | Social | SEIU Master Trust | Report on Lobbying Payments and Policy | Against | 37.03% |
5/2/22 | Governance | Legal & General Invest. Mgmt. America, Inc. | Independent Board Chair | Against | 34.54% |
5/2/22 | Social | CommonSpirit Health | Disclose Lobbying Activities & Alignment with Public Policy Positions | Against | 34.00% |
5/2/22 | Governance | Trinity Health | Report Oversight of Risks Related to Anticompetitive Pricing Strategies | Against | 22.78% |